A new study demonstrates that anti-nephrin autoantibodies are not merely markers but also actively contribute to the pathogenesis of minimal change disease and primary focal segmental glomerulosclerosis. This insight not only provides a non-invasive diagnostic alternative to kidney biopsies, but also suggests potential for novel targeted therapies.
